TSLA
Tesla
-- 416.801 NVDA
NVIDIA
-- 148.070 PLTR
Palantir
-- 80.980 AAPL
Apple
-- 224.560 TEM
Tempus AI
-- 54.430 
NEWS
Telomir Pharmaceuticals Confirms Lifespan Restoration and Normalization of Accelerated Aging in Preclinical Model of Progeria (A Rare Genetic Disorder Causing Rapid Aging)
Tuesday, 7th January at 8:00 am
MIAMI, FL / ACCESSWIRE / January 7, 2025 / Telomir Pharmaceuticals, Inc. (NASDAQ: TELO) ("Telomir"), an emerging leader in age-reversal science focused on treating the root causes of diseases rather than just their symptoms, announced today potentially groundbreaking findings from a preclinical progeria lifespan study conducted in collaboration with Nagi Bioscience SA. Utilizing C. elegans (nematode) models, in which the study demonstrated restoration of shortened lifespan and normalization of accelerated aging with Telomir-1.
The study was conducted in nematodes (C. elegans) with a mutation in the wrn-1 gene, which is equivalent to a gene in humans associated with Werner Syndrome (a form of Progeria). Compared to normal (wild-type) nematodes, those with wrn-1 depletion showed a significantly reduced mean and median lifespan. Utilizing advanced in vivo microfluidic technology, the study demonstrated lifespan restoration and normalization of accelerated agingeffects in wrn-1-mutated nematodes treated with Telomir-1. The treatment effectively restored longevity to levels not significantly different from normal animals. These effects included an extended healthy lifespan and the normalization of several physiological parameters, such as movement velocity and tail amplitude.
Laurent Mouchiroud, Ph.D., Co-founder and CSO of Nagi Bioscience SA, commented, "The analysis confirms that Telomir-1 not only restores lifespan but also effectively counters the decline observed in untreated populations. These findings underscore Telomir-1's potential to transform how we address age-related conditions by targeting their underlying cellular mechanisms."
Tuesday, 7th January at 8:00 am
MIAMI, FL / ACCESSWIRE / January 7, 2025 / Telomir Pharmaceuticals, Inc. (NASDAQ: TELO) ("Telomir"), an emerging leader in age-reversal science focused on treating the root causes of diseases rather than just their symptoms, announced today potentially groundbreaking findings from a preclinical progeria lifespan study conducted in collaboration with Nagi Bioscience SA. Utilizing C. elegans (nematode) models, in which the study demonstrated restoration of shortened lifespan and normalization of accelerated aging with Telomir-1.
The study was conducted in nematodes (C. elegans) with a mutation in the wrn-1 gene, which is equivalent to a gene in humans associated with Werner Syndrome (a form of Progeria). Compared to normal (wild-type) nematodes, those with wrn-1 depletion showed a significantly reduced mean and median lifespan. Utilizing advanced in vivo microfluidic technology, the study demonstrated lifespan restoration and normalization of accelerated agingeffects in wrn-1-mutated nematodes treated with Telomir-1. The treatment effectively restored longevity to levels not significantly different from normal animals. These effects included an extended healthy lifespan and the normalization of several physiological parameters, such as movement velocity and tail amplitude.
Laurent Mouchiroud, Ph.D., Co-founder and CSO of Nagi Bioscience SA, commented, "The analysis confirms that Telomir-1 not only restores lifespan but also effectively counters the decline observed in untreated populations. These findings underscore Telomir-1's potential to transform how we address age-related conditions by targeting their underlying cellular mechanisms."
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
7009
Followers
46
Following
76K
Visitors
Follow
Discussing
Trump 2.0 Era: What's the next opportunity in the markets?
▪️Could Trump's crypto policies potentially benefit the crypto market? ▪️Might his tariff policies have a positive effect on Chinese stocks
Michael McCarthy CCO
Jan 3 11:57
Ask a strategist - Trump's first day